Latest Advisory

  • Joint FDA-HFSRB Advisory No. 2015-001 || Accredited Health Facilities for Human Stem Cell and Cell-Based or Cellular Therapies and Approved Indications

    Joint FDA-HFSRB Advisory No. 2015-001 || Accredited Health Facilities for Human Stem Cell and Cell-Based or Cellular Therapies and Approved Indications

    Read more

  •  FDA Advisory No. 2015-063 || RECTIFICATION TO FDA ADVISORY NO. 2015-044 “RECALL OF SPECIFIC DRUG PRODUCTS OF MORISHITA-SEGGS PHARMACEUTICALS, INC. MANUFACTURED FROM JANUARY 2014 UP TO THE PRESENT”

    FDA Advisory No. 2015-063 || RECTIFICATION TO FDA ADVISORY NO. 2015-044 “RECALL OF SPECIFIC DRUG PRODUCTS OF MORISHITA-SEGGS PHARMACEUTICALS, INC. MANUFACTURED FROM JANUARY 2014 UP TO THE PRESENT”

    Read more

  •  FDA Advisory No. 2015-062 || PUBLIC WARNING AGAINST UNREGISTERED FOOD SUPPLEMENTS THAT ARE OFFERED FOR SALE IN THE MARKET AND THRU THE INTERNET

    FDA Advisory No. 2015-062 || PUBLIC WARNING AGAINST UNREGISTERED FOOD SUPPLEMENTS THAT ARE OFFERED FOR SALE IN THE MARKET AND THRU THE INTERNET

    Read more

  • FDA Advisory No. 2015-061 || TERMINATION OF PRODUCT RECALL ORDER ISSUED ON SPECIFIC BATCHES OF TETRAHYDROZOLINE HCl (EYE-MO RED EYES FORMULA) 0.05% OPHTHALMIC SOLUTION (EYE DROPS)

    FDA Advisory No. 2015-061 || TERMINATION OF PRODUCT RECALL ORDER ISSUED ON SPECIFIC BATCHES OF TETRAHYDROZOLINE HCl (EYE-MO RED EYES FORMULA) 0.05% OPHTHALMIC SOLUTION (EYE DROPS)

    Read more

  • FDA Advisory No. 2015-060 || TERMINATION OF PRODUCT RECALL ORDER ISSUED ON SPECIFIC LOT JKN0969B OF DOXORUBICIN HYDROCHLORIDE 2 mg/mL (20 mg/10 mL) PEGYLATED LIPOSOMAL CONCENTRATE FOR I.V. INFUSION (CASPRIA)

    FDA Advisory No. 2015-060 || TERMINATION OF PRODUCT RECALL ORDER ISSUED ON SPECIFIC LOT JKN0969B OF DOXORUBICIN HYDROCHLORIDE 2 mg/mL (20 mg/10 mL) PEGYLATED LIPOSOMAL CONCENTRATE FOR I.V. INFUSION (CASPRIA)

    Read more

Additional Instruction for Letters, Commercial Samples, and Approved Labels for Post-Marketing Surveillance (PMS) Purposes to be Submitted to the Center for Drug Regulation and Research

Consistent with the issuance of FDA Memorandum dated 14 august 2014 regarding the Receiving of Product Application and Letter, and to facilitate the processing of related services and regulatory processes, all concerned stakeholders are requested to comply with the following additional instructions:

- For letters, kindly provide contact details (e.g. telephone number(s) and/or e-mail address(es). This will allow online viewing of the letter vial DocTrack at http://www.fda.gov.ph/doctrack-status-know-the-status-of-your-application and minimize the need for the follow-up on the part of the stakeholder.

- For labels submitted as part of post-approval commitment, kindly include copies of the labeling materials as corrected by CDRR. This will facilitate the review and filling of the process of FDA.

- For commercial samples submitted as part of post-approval commitment, kindly include copies of the approved labeling material(s). This will facilitate the review and filling process of FDA.

As part of transparency and rendering faster processing of the above mentioned submissions, instead of issuing acknowledgement letters, FDA shall acknowledgement via DocTrack.

For your information and compliance

Attachments:
Download this file (announcement.pdf)announcement.pdf

Share Us on

Submit to FacebookSubmit to Google PlusSubmit to Twitter